- Programme Sector
- HealthUnionMedical researchPharmaceutical industryPublic healthPublic procurementScientific researchTendering
Financed by HERA’s annual work plan for 2022, the Commission, in cooperation with HaDEA, is launching EU FAB, with the objective to ensure that sufficient and agile manufacturing capacities for different vaccine types are kept operational and can be activated quickly in case of a public health emergency.
The purpose of this framework contract is to reserve the capacity and a priority right to manufacture vaccines for a minimum of 450 million doses under all lots.
Estimated total value: €160 million
Duration of the contract: 48 months